Journal
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Volume 143, Issue 2, Pages 241-247Publisher
OXFORD UNIV PRESS INC
DOI: 10.1309/AJCPQ2NJD3PXFTUG
Keywords
Activated partial thromboplastin time; Coagulation assay; Direct factor Xa inhibitor; Monitoring; Prothrombin time; Thrombin generation assay
Categories
Funding
- Daiichi Sankyo
Ask authors/readers for more resources
Objectives: Edoxaban, an oral direct factor Xa inhibitor, does not require routine monitoring. However, assessment of the anticoagulant effects may be required in certain situations. Methods: We investigated the effects of edoxaban on prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin generation using human platelet-poor plasma (PPP) or platelet-rich plasma (PRP). Results: Edoxaban concentration-dependently prolonged PT and aPTT. There was a considerable variation in the magnitude of PT prolongation among the reagents used The variability in aPTT prolongation among the reagents was smaller than that of PT Edoxaban concentration-dependently inhibited thrombin generation, with a more potent effect seen in PPP than in PRP. Thrombin generation assay was three times more sensitive to edoxaban than PT and aPTT. Conclusions: PT had disadvantages of a large variability among different PT reagents. aPTT could be used as a conventional and convenient test with a smaller variation among reagents. Thrombin generation was the most sensitive assay.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available